TARS Stock Analysis: Buy, Sell, or Hold?
TARS - Tarsus Pharmaceuticals, Inc. Common Stock
$70.22
0.07 (0.10%)
▲
5d:
+4.87%
30d:
-8.27%
90d:
-14.71%
BUY
HIGH Confidence
Analysis Updated: Apr 1, 2026 12:00 AM ET
Earnings: May 07, 2026
Smart Money Accumulation
TARS is down 9.0% this week, but smart money is accumulating calls. Top strike: $80 2026-04-17 with 29 OI. Call ratio: 82% View Scanner →
Strength: 7.7/10
Get Alerted When TARS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: TARS trading at deep discount. Market pricing in -19.8% annual earnings decline, creating value opportunity for patient investors.
✅ BUY SIGNAL: TARS trading at deep discount. Market pricing in -19.8% annual earnings decline, creating value opportunity for patient investors.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$101.16
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$62.82
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: TARS is currently trading at $70.22, which is considered fair relative to its 30-day fair value range of $66.41 to $74.57. From a valuation perspective, the stock is trading at a discount (Forward PE: 24.3) compared to its historical average (47.0). Remarkably, the market is currently pricing in an annual earnings decline of 19.8% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, TARS is in a strong downtrend. The price is approaching resistance at $72.14. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: TARS has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (21th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $95.11 (+35.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, TARS is in a strong downtrend. The price is approaching resistance at $72.14. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: TARS has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (21th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $95.11 (+35.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$66.41 -
$74.57
Company Quality Score
60/100
(BUY)
Options IV Signal
21th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
86.5%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 21th percentile)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 35.4% below Wall St target ($95.11)
Fair Price Analysis
30-Day Fair Range
$66.41 -
$74.57
Current vs Fair Value
FAIR
Expected Move (7 Days)
±$7.18
(10.2%)
Support & Resistance Levels
Support Level
$61.51
Resistance Level
$72.14
Current Trend
Strong Downtrend
Technical data as of
Apr 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
24.31
Wall Street Target
$95.11
(+35.4%)
Revenue Growth (YoY)
128.4%
Profit Margin
-14.7%
Valuation Discount vs History
-19.8% cheaper
PE vs Historical
24.3 vs 47.0
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-19.8%
(market-implied from PE analysis)
1-Year Target
$63.20
(-10%)
2-Year Target
$56.88
(-19%)
3-Year Target
$51.19
(-27%)
3-Yr Target (if PE normalizes)
(PE: 24→47)
$98.95
(+41%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 24.3 to 47.0
Stabilization Target:
$135.74
(+93.3%)
PE Expansion Potential:
+93.3%
Share & Embed Analysis
Last updated: April 02, 2026 9:00 AM ET
Data refreshes hourly during market hours. Next update: 10:00 AM
Data refreshes hourly during market hours. Next update: 10:00 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TARS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
William J Phd Link
SELL
12500 shares
2026-03-16
Bobak R Azamian
SELL
6000 shares
2025-12-24
Dianne C Whitfield
SELL
7397 shares
2025-12-16
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$21 | 56 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1018 | 55 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$30 | 59 HOLD |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$132 | 56 HOLD |
Advanced TARS Option Strategies
Professional options setups generated by AI based on today's TARS price and gamma walls.
